Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 996-1003

  Högfeldt, Therese ^a   Bahnassy, Abeer A ^b   Kwiecinska, Anna ^a   Österborg, Anders ^a   Tamm, Katja Pokrovskaja ^a   Porwit, Anna ^c   Zekri, Abdel Rahman N ^d   Lundahl, Joachim ^a   Khaled, Hussein M ^d   Mellstedt, Håkan ^a   Moshfegh, Ali ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Diffuse large B cell lymphoma; Gene expression; Inflammation; STAT; Viral infections

Indexed keywords

STAT3 PROTEIN; STAT5B PROTEIN; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; EGYPT; ENVIRONMENTAL EXPOSURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; LARGE CELL LYMPHOMA; LYMPH NODE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL FACTOR; SWEDEN; VIRUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; EGYPT; ENVIRONMENT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE-ENVIRONMENT INTERACTION; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SWEDEN; VIRUS DISEASES;

EID: 84876211956     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.738365     Document Type: Article

References (45)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classifcation Project. Blood 1997;89:3909-3918.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identif ed by gene expression profling. Nature 2000;403:503-511.
3. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996.
4. Naresh KN, Advani S, Adde M, et al. Report of an International Network oficancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countries. Blood Cells Mol Dis 2004;33:330-337.
5. Gisbert JP, Garcia-Buey L, Arranz R, et al. The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Eur J Gastroenterol Hepatol 2004;16:135-138.
6. Wong HH, Wang J. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma 2009;50:335-340.
7. Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 2010; 51: 66-72.
8. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-6534.
9. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003;102:996-999.
10. Jarrett RF. Viruses and lymphoma/leukaemia. J Pathol 2006;208: 176-186.
11. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010; 10: 878-889.
12. Zhang JY, Dai M, Wang X, et al. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol 1998;27:574-578.
13. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inf ammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006; 15:2069-2077.
14. Ferreri AJ, Dognini GP, Campo E, et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in Different geographical regions. Haematologica 2007;92:486-492.
15. Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, et al. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in Different European regions: a case-control study of the International Extranodal Lymphoma Study Group. Hematol Oncol 2012;30:137-142.
16. Nicolaides C, Fountzilas G, Zoumbos N, et al. diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 1998;55: 405-415.
17. Tilly H, Dreyling M. diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): v172-v174.
18. Hans CP, Weisenburger DD, Greiner TC, et al. Conf rmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282.
19. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-207.
20. Jacobson TA, Lundahl J, Mellstedt H, et al. Gene expression analysis using long-term preserved formalin-fixed and paraf n-embedded tissue of non-small cell lung cancer. Int J Oncol 2011; 38: 1075-1081.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
22. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
23. Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011; 24: 1046-1054.
24. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009;40:653-661.
25. Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41: 352-357.
26. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003;27:16-26.
27. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007;13:5124-5132.
28. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-978.
29. Darnell JE Jr. STATs and gene regulation. Science 1997;277: 1630-1635.
30. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. JVirol 1999;73:8469-8475.
31. Koeberlein B, zur Hausen A, Bektas N, et al. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inf ammation in the liver. Virus Res 2010;148:51-59.
32. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996;88:809-816.
33. Yamashita H, Nishio M, Ando Y, et al. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006;13:885-893.
34. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008;111:3701-3713.
35. Li P, Harris D, Liu Z, et al. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 2010;5:e11859.
36. Bock CT, Toan NL, Koeberlein B, et al. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology 2008; 51: 432-443.
37. Horvath CM. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem 2004;271:4621-4628.
38. Ulane CM, Rodriguez JJ, Parisien JP, et al. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. JVirol 2003;77:6385-6393.
39. Sobti RC, Singh N, Hussain S, et al. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis. J Recept Signal Transduct Res 2010;30:178-188.
40. Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 1993;85:862-874.
41. Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Invest 2008; 26: 306-316.
42. Frederiksen BL, Dalton SO, Osler M, Steding-Jessen M, de Nully Brown P. Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark- A nationwide study. Br J Cancer 2012;106:988-995.
43. Choudhury A, Derkow K, Daneshmanesh AH, et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol 2010;151:327-335.
44. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008;123:1190-1195.
45. Shabani M, Asgarian-Omran H, Vossough P, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms'tumor gene 1 (WT1) in Different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 2008; 49: 1360-1367.